To include your compound in the COVID-19 Resource Center, submit it here.

Bristol-Myers reports AD data for gamma secretase inhibitor

Based on data from the Phase II CN156-013 trial in 209 patients with mild to moderate Alzheimer's disease,

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE